Dr. Justin Fischedick discusses his research and what we can expect from his talk “Terpenoids of Cannabis sativa L., Analysis and Applications” during the Spring 2020 CANN Virtual Symposium in The Second Annual ElSohly Award session on Wednesday, May 6.
Justin Fischedick holds a Bachelor’s of Science from the State University New York College of Environmental Science and Forestry in Syracuse, New York, a Master of Science in Biology and a Doctoral Degree from Leiden University, Leiden, The Netherlands. Dr. Fischedick’s research interests are in the areas of biotechnology, natural products chemistry, pharmacognosy, and analytical chemistry. The results of his research have been published in several peer-reviewed scientific journals and publications. He has presented his research at national and international scientific conferences. Dr. Fischedick was involved in several research projects investigating the chemical composition and quality control of medicinal cannabis and other medicinal plants during his graduate studies at Leiden University. After completing his PhD, his postdoctoral research at the Institute of Biological Chemistry at Washington State University focused on analytical methods and biosynthesis of medicinally valuable compounds from plants. From 2014 to 2018, Dr. Fischedick was lead scientist at a cannabis testing laboratory, Excelsior Analytical Laboratory in Union City, California. Currently, he is employed as a senior scientist at Integrated Analytical Solutions, a GxP compliant contract research organization based in Berkeley California focused in areas of bioanalysis, drug metabolism, and analytical chemistry. Here he discusses some of his research and what we can expect from his presentation on May 6.
What will your talk at the CANN symposium be focused on?Justin Fischedick: I plan to discuss a bit of the historical research on cannabis terpenes and how this has inspired some of the current research going on with cannabis terpenes. I will describe some research I’ve done regarding cannabis terpenes both as a graduate student and in industry working at cannabis analytical laboratories. I’ll describe how to analyze and properly identify these compounds. I’d also like to spend a bit of time discussing some of the statistical approaches you can use to analyze large datasets and some of the chemotaxonomic uses of such approaches.
What do you hope attendees at the symposium will take away from your talk?
Fischedick: I hope attendees get a broader understanding of some of the literature and studies that have already been done on cannabis terpenes. I find a lot of information regarding the analysis of terpenes in cannabis that is easily accessible online is coming mainly from the cannabis industry or instrument vendors. The information coming from both of these sources while sometimes useful can also be misleading regarding the most appropriate analytical technique or potential medicinal or therapeutic effects of these compounds. I’d like to clear up some of these misconceptions.
How will winning the ElSohly Award impact your research efforts or future projects?
Fischedick: I think obtaining the ElSohly Award is an honor and I thank CANN for it. It is nice to get recognition for work I’ve done. I can’t really say how it might impact my future except it is always good to bring attention to sound scientific research especially in a field as unique and strange as the cannabis industry.
How did you get started with cannabis research? Can you tell us about some of your early research projects investigating the chemical composition and quality control of medicinal cannabis at Leiden University?
Fischedick: I got started in cannabis when I was a graduate student at Leiden University in the city of Leiden, which is in The Netherlands. I was working at the Institute of Biology, Natural Products Laboratory. The main focus of the lab’s research was pharmacognosy, phytochemistry, plant biotechnology, and basic natural products research. They had a project involving medicinal cannabis that I ended up working on for my Master’s thesis and a big part of my PhD thesis as well. The overall goal of the project was to study how to develop cannabinoid-based medicines and the standardization of herbal cannabis for medicinal applications. I mainly worked on analysis and purification of cannabinoids and terpenes found in cannabis. I also did research on administration forms for cannabis such as studying the vapor products by herbal vaporizers and some work on the bioactivity of cannabinoids.
Can you tell us more about your current research involving cannabis and what you hope to study in the future?
Fischedick: I’m not solely focused on cannabis at the moment although I am working on a number of method validations to meet the state of California regulatory requirements for a cannabis lab testing at an analytical laboratory in Berkeley California called Integrated Analytical Solutions. The main focus of the company has been bioanalytical, drug metabolism, and GxP pharmaceutical testing. I am working on a number of those types of projects as we also expand into cannabis testing. I think learning about GLP regulations has given me valuable insight into how to apply such approaches to cannabis and cannabis products analytical testing.
Dr. Fischedick will be presenting his talk “Terpenoids of Cannabis sativa L., Analysis and Applications” during the Spring 2020 CANN Virtual Symposium in The Second Annual ElSohly Award session on Wednesday, May 6.
Register for free here: https://www.cannabissciencetech.com/e-learning-tools/spring-2020-cann-virtual-symposium.
Cannabis, US Presidential Election 2024, and Beyond: A Roundtable Discussion, Part II
December 17th 2024With the recent 2024 presidential election behind us, the future of cannabis still has many unknowns moving forward and questions still to be discussed. In this roundtable discussion with four knowledgeable industry leaders, we explore the nuanced political landscape of cannabis legalization and rescheduling in the context of the election, including state and federal policies and possible paths forward for testing standardization. Join us in the second part of a compilation of responses from Kim Anzarut, CQA, CP-FS, CEO of Allay Consulting; Susan Audino, PhD, founder of S.A. Audino & Associates, LLC; Zacariah Hildenbrand, PhD, research Professor at the University of Texas at El Paso; and David Vaillencourt, CEO of The GMP Collective.
Cannabis, US Presidential Election 2024, and Beyond: A Roundtable Discussion, Part I
December 16th 2024With the recent 2024 presidential election behind us, the future of cannabis still has many unknowns moving forward and questions still to be discussed. In this roundtable discussion with four knowledgeable industry leaders, we explore the nuanced political landscape of cannabis legalization and rescheduling in the context of the election. We discuss what drives support or opposition from both sides of the aisle, the complexities of balancing state and federal priorities, and more. Join us in the first part of a compilation of responses from Kim Anzarut, CQA, CP-FS, CEO of Allay Consulting; Susan Audino, PhD, founder of S.A. Audino & Associates, LLC; Zacariah Hildenbrand, PhD, research Professor at the University of Texas at El Paso; and David Vaillencourt, CEO of The GMP Collective.
Empowering Women in Cannabis: Susan Audino, PhD, on Inclusivity, Integrity, and Industry Challenges
December 11th 2024Founder of S. A. Audino & Associates, LLC, Susan Audino, PhD, recently co-founded Saturn Scientific, LLC, a collaboration of five experienced individuals providing unbiased evaluations on the data and science for stakeholders in the cannabis industry. In this interview with Cannabis Science and Technology, Dr. Audino shares her unexpected path into analytical science and the cannabis industry as well as the obstacles she’s faced throughout her career. She highlights the gender bias she’s observed, such as unequal recognition of credentials and workplace challenges, while advocating for inclusivity and mentorship to empower women in science. Additionally, Dr. Audino recounts her experiences of navigating the male-dominated cannabis space, pushing for transparency, collaboration, and integrity in laboratory practices. Ultimately, Audino believes fostering mutual respect and knowledge-sharing is vital for the industry’s growth and resilience.
Collaboration, Gender Diversity, and Progress: Julie Kowalski on Advancing Cannabis Science
December 10th 2024In this interview with Cannabis Science and Technology, Julie Kowalski, an experienced analytical chemist, discusses her path into the cannabis industry, starting with early work in gas chromatography. Kowalski reflects on her perspectives as a female scientist, highlighting biases she’s experienced and the benefits of gender inclusivity in the cannabis space. Greater unity and professionalism could benefit the industry as a whole, she explains. She also encourages collaboration and more women in leadership positions in order to build a stronger scientific community, and also urges women to advocate for themselves, noting that women in cannabis face unique obstacles but often demonstrate consensus-building strategies and solutions.
Gender Diversity and Innovation in the Cannabis Space: Insights from Tess Eidem, PhD
December 9th 2024Cannabis Science and Technology sat down with Tess Eidem, PhD, PCQI, member of Saturn Scientific, LLC, to discuss her journey from antibiotic research to cannabis microbiology and her observations throughout her career. Dr. Eidem highlights challenges women face in this male-dominated industry, including limited representation in leadership roles and frequent experiences of bias and discrimination. She emphasizes the importance of gender diversity in fostering innovation, improving product safety, and addressing women’s health needs in cannabis applications. Her advice to women scientists is to build strong professional relationships and carefully evaluate work environments to advance their careers in this evolving and often challenging space.